Atezolizumab and Bevacizumab in Hepatocellular Carcinoma, Durvalumab, HCC - Hepatocellular Carcinoma, Immune Checkpoint Inhibitor-Induced Dermatitis, Immune Checkpoint Therapy, Immunotherapy
Conditions
Keywords
Immune check points inhibitors efficacy, Immune check points inhibitors safety, Response evaluation in hepatocellular carcinoma
Brief summary
This study aims to evaluate the response to immunotherapy in HCC, assess the toxicity profile and measure overall survival within the study period. The primary end point is evaluation of progression free survival in HCC patients receiving immunotherapy. The secondary end point is to assess overall survival within the study period, duration of response and the response rate. The tertiary end point is to assess the toxicity profile.
Detailed description
Treatment starts after MDT discussion and approval for diagnosis, staging and treatment protocol. * This study includes patients with advanced HCC who will receive their first line of treatment. Cases will receive atezolizumab (1200 mg) + bevacizumab (15mg/kg) every 3 weeks or Tremilimumab (300 mg single dose IV infusion on first day only) + Durvalumab (1500 mg on the same day then every 4 weeks) according to eligibility criteria. * Cases will be evaluated every cycle clinically and laboratory. * Baseline investigations will include; 1. Laboratory ; 1. CBC 2. liver enzymes (ALT, AST, alkaline phosphatase, GGT) 3. liver function tests (serum albumin, serum bilirubin total and direct, INR) 4. kidney function tests (serum creatinine, BUN, 24 hrs urinary protein) 5. electrolytes Na, K, Ca) t) Others; HBAlc, Thyroid function tests (TSH, T3, T4), Alpha feto protein 2. Radiological imagings; 1. Triphasic CT and/or dynamic MRI abdomen 2. PET scan or CT chest and bone scan 3. ECG, ECHO, Upper GI endoscopy * Every 3 months patients will undergo laboratory and radiological investigations, assessed by 2 blinded radiologists. * The degree of adverse events was evaluated according to The Common Terminology Criteria for Adverse Events version 5.0.(30) ,which rates toxicity on a scale from 1 to 5, with ascending order of severity. This will be managed according to toxicity grade whether treatment interruption, dose reduction or discontinuation. * Study treatment to be continued until disease progression, unacceptable toxicity, serious inter-current illness, patient request for discontinuation, or need for any other anticancer agent other than study treatment.
Interventions
None listed
Sponsors
Ain Shams University
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Age ≥ 18. * Hepatocellular carcinoma based on histological diagnosis or the typical findings on radiological imaging including enhanced dynamic computed tomography (CT) and/or dynamic magnetic resonance imaging (MRI). * ECOG Performance status of 0 or 1 * Patients with Child-Pugh class A * BCLC stage B with diffuse, infiltrative, or extensive bilobar involvement * BCLC stage B with tumor progression after failure of TACE * BCLC stage C * No prior systemic therapy for HCC * Additional eligibility criteria; Hb ≥ 9 g/dl, platelets ≥ 75x10%/1, ANC ≥ 1.5 x10% for Atezolizumab/bevacizumab and ANC ≥ 1x10%1 for Durvalumab/Tremilimumab, INR ≤ 2, albumin ≥ 2.8 g/dl, total bilirubin ≤ 3 mg/dl, AST and ALT ≤ 5 x ULN, creatinine clearance ≥ 50 ml/min * Additional criteria for Atezolizumab/Bevacizumab; upper endoscopy showing no risky high grade esophageal varices (within 6 months of first dose) unless adequately managed
Exclusion criteria
* Performance status ≥ 2 * Patients with Child-Pugh class B or C * BCLC stage A or D * Active tuberculosis or active human immunodeficiency virus (HIV) infection * HCV or HBV infection except if; HBV DNA \< 500 IU/ml or started anti- HBV treatment for a minimum of 14 days prior to first dose * Severe infection requiring hospitalization within 4 weeks prior to first dose * History of allogenic stem cell or solid organ transplant * Treatment with systemic immunostimulatory or immunosuppressive medication * Active and history of autoimmune disease or immune deficiency * Receiving a live, attenuated vaccine within 4 weeks prior to first dose * History of idiopathic pulmonary fibrosis, or evidence of active pneumonitis * Central nervous system metastases * Symptomatic hypercalcemia (ionized calcium \> 1.5 mmol/1 (6 mg/dl), calcium \> 12 mg/dl, or corrected serum calcium \> ULN) * History of severe allergic anaphylactic reactions to chimeric or humanized antibodies or fusion proteins * Prior history of hypertensive crisis or hypertensive encephalopathy * Cardiac conditions, such as severe heart failure, unstable angina, recent myocardial infarction, severe arrhythmias * Evidence of bleeding diathesis or coagulopathy Special for atezolizumab + bevacizumab * Risky esophageal or gastric varies unless adequately managed * Severe portal hypertensive gastropathy which is associated with decline in hemoglobin, uniess controlled * Severe proteinuria ≥ 3.5 g/24 hrs or by dipstick 4+ proteinuria, according to CTCAE. Special for tremelimumab + durvalumab * Main portal vein tumor thrombosis
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Progression free survival in HCC patients receiving immunotherapy. | From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 12 months | Progression-free survival (PFS) is defined as the time elapsed between treatment initiation and tumor progression or death from any cause. Progression (i.e., PD) was defined as presence of new measurable/non- measurable lesions, or ≥ 20% increase in tumour burden relative to nadir |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| overall survival within the study period, | From date of randomization until the date of loss of follow up or date of death from any cause, whichever came first, assessed up to 12 months | Overall survival (OS) is defined as time from diagnosis to either last follow-up or /death |
| Response rate | From enrollment to study till 1 year or treatment | Response rate is defined as the proportion of patients with a complete response/immune complete response or partial response/ immune partial response to treatment |
Other
| Measure | Time frame | Description |
|---|---|---|
| Assess the toxicity profile of immunotherapy | From enrollment to 1 year of treatment | The degree of adverse events was evaluated according to The Common Terminology Criteria for Adverse Events version 5.0. ,which rates toxicity on a scale from 1 to 5, with ascending order of severity. This will be managed according to toxicity grade whether treatment interruption, dose reduction or discontinuation. |
Countries
Egypt
Outcome results
None listed